Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation.
Key findingLiraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehens
What the researchers found
Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Patients aged 12 to 17.9 years with severe obesity. Glycemic control assessed by continuous glucose monitoring (CGM).
How the study worked
In publication.
Who was studied
Adolescents aged 12-17.9 years with severe obesity
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.
Journal of clinical research in pediatric endocrinology, 17(1), 68-75
Citation
Apperley, Louise; Parkinson, Jennifer; Senniappan, Senthil. (2025). Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.. Journal of clinical research in pediatric endocrinology, 17(1), 68-75. https://doi.org/10.4274/jcrpe.galenos.2024.2023-10-10